- 10x Genomics ( NASDAQ: TXG ) is trading 10% higher after the company posted better-than-expected Q4 result, helped by higher consumables revenue in the Americas and EMEA.
- Q4 GAAP EPS of -$0.15 beat by $0.17, while revenue of $156.2M (+8.9% Y/Y) beats by $8.03M.
- Gross margin was 76% for the fourth quarter, as compared to 81%, a year earlier.
- 10x Genomics expects full year 2023 revenue to be in the range of $580M to $600M vs $596.51M consensus, representing 12% to 16% growth over full year 2022 revenue.
- Press Release
For further details see:
10x Genomics rises on Q4 earnings beat